SG11201604573WA - Serine/threonine kinase inhibitors - Google Patents
Serine/threonine kinase inhibitorsInfo
- Publication number
- SG11201604573WA SG11201604573WA SG11201604573WA SG11201604573WA SG11201604573WA SG 11201604573W A SG11201604573W A SG 11201604573WA SG 11201604573W A SG11201604573W A SG 11201604573WA SG 11201604573W A SG11201604573W A SG 11201604573WA SG 11201604573W A SG11201604573W A SG 11201604573WA
- Authority
- SG
- Singapore
- Prior art keywords
- serine
- kinase inhibitors
- threonine kinase
- threonine
- inhibitors
- Prior art date
Links
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912905P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068452 WO2015085007A1 (en) | 2013-12-06 | 2014-12-03 | Serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604573WA true SG11201604573WA (en) | 2016-07-28 |
Family
ID=52350292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604573WA SG11201604573WA (en) | 2013-12-06 | 2014-12-03 | Serine/threonine kinase inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9867833B2 (enExample) |
| EP (1) | EP3077401B1 (enExample) |
| JP (2) | JP6449293B2 (enExample) |
| KR (1) | KR102359759B1 (enExample) |
| CN (1) | CN106029672B (enExample) |
| AR (1) | AR098647A1 (enExample) |
| AU (1) | AU2014360455B2 (enExample) |
| BR (1) | BR112016012844B1 (enExample) |
| CA (1) | CA2932729C (enExample) |
| CL (1) | CL2016001368A1 (enExample) |
| CR (1) | CR20160309A (enExample) |
| EA (1) | EA031243B1 (enExample) |
| IL (1) | IL246017B (enExample) |
| MA (1) | MA39170B1 (enExample) |
| MX (1) | MX368443B (enExample) |
| MY (1) | MY176049A (enExample) |
| PE (1) | PE20160886A1 (enExample) |
| PH (1) | PH12016501071B1 (enExample) |
| SG (1) | SG11201604573WA (enExample) |
| TW (1) | TWI557126B (enExample) |
| UA (1) | UA120506C2 (enExample) |
| WO (1) | WO2015085007A1 (enExample) |
| ZA (1) | ZA201604461B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2884766A1 (en) | 2012-10-16 | 2014-04-24 | Daniel Jon Burdick | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| KR102396710B1 (ko) * | 2013-12-30 | 2022-05-10 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 저해제 |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| PE20181288A1 (es) | 2015-11-09 | 2018-08-07 | Astrazeneca Ab | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CA3140475A1 (en) * | 2019-06-06 | 2020-12-10 | Wei-Guo Su | Tricyclic compounds and their use |
| CN120682245A (zh) * | 2021-02-03 | 2025-09-23 | 江苏恒瑞医药股份有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| CA2622571A1 (en) * | 2005-09-15 | 2007-03-22 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| DE602008003055D1 (de) * | 2007-05-31 | 2010-12-02 | Nerviano Medical Sciences Srl | Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| BR112013021896A2 (pt) | 2011-02-28 | 2016-11-08 | Array Biopharma Inc | inibidores de serina/treonina cinase |
| CN103958502B (zh) | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
| SI2820009T1 (en) | 2012-03-01 | 2018-05-31 | Array Biopharma, Inc. | Serine / Threonine kinase inhibitors |
| US9388171B2 (en) | 2012-08-27 | 2016-07-12 | Genetech, Inc. | Serine/threonine kinase inhibitors |
| CA2884766A1 (en) | 2012-10-16 | 2014-04-24 | Daniel Jon Burdick | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| KR102396710B1 (ko) | 2013-12-30 | 2022-05-10 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 저해제 |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| AR099989A1 (es) | 2014-04-09 | 2016-08-31 | Genentech Inc | Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus sales |
-
2014
- 2014-12-03 JP JP2016536560A patent/JP6449293B2/ja active Active
- 2014-12-03 PE PE2016000741A patent/PE20160886A1/es unknown
- 2014-12-03 UA UAA201607281A patent/UA120506C2/uk unknown
- 2014-12-03 MY MYPI2016001051A patent/MY176049A/en unknown
- 2014-12-03 BR BR112016012844-3A patent/BR112016012844B1/pt not_active IP Right Cessation
- 2014-12-03 CN CN201480074890.9A patent/CN106029672B/zh active Active
- 2014-12-03 AU AU2014360455A patent/AU2014360455B2/en not_active Ceased
- 2014-12-03 US US14/559,786 patent/US9867833B2/en active Active
- 2014-12-03 CA CA2932729A patent/CA2932729C/en active Active
- 2014-12-03 CR CR20160309A patent/CR20160309A/es unknown
- 2014-12-03 MA MA39170A patent/MA39170B1/fr unknown
- 2014-12-03 EP EP14827591.0A patent/EP3077401B1/en active Active
- 2014-12-03 EA EA201691177A patent/EA031243B1/ru not_active IP Right Cessation
- 2014-12-03 MX MX2016007352A patent/MX368443B/es active IP Right Grant
- 2014-12-03 SG SG11201604573WA patent/SG11201604573WA/en unknown
- 2014-12-03 WO PCT/US2014/068452 patent/WO2015085007A1/en not_active Ceased
- 2014-12-03 KR KR1020167017847A patent/KR102359759B1/ko not_active Expired - Fee Related
- 2014-12-05 TW TW103142501A patent/TWI557126B/zh not_active IP Right Cessation
- 2014-12-05 AR ARP140104549A patent/AR098647A1/es unknown
-
2016
- 2016-06-03 CL CL2016001368A patent/CL2016001368A1/es unknown
- 2016-06-05 IL IL24601716A patent/IL246017B/en active IP Right Grant
- 2016-06-06 PH PH12016501071A patent/PH12016501071B1/en unknown
- 2016-06-30 ZA ZA2016/04461A patent/ZA201604461B/en unknown
-
2017
- 2017-09-14 US US15/705,104 patent/US10278975B2/en active Active
-
2018
- 2018-11-09 JP JP2018211421A patent/JP2019034970A/ja active Pending
-
2019
- 2019-02-27 US US16/286,955 patent/US10517878B2/en active Active
- 2019-11-11 US US16/680,221 patent/US10842799B2/en active Active
-
2020
- 2020-10-20 US US17/075,380 patent/US11376260B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201508847B (en) | Serine/threonine kinase inhibitors | |
| IL245846B (en) | syk inhibitors | |
| IL243578A0 (en) | syk inhibitors | |
| SG11201508125XA (en) | Protein kinase inhibitors | |
| ZA201604461B (en) | Serine/threonine kinase inhibitors | |
| ZA201506156B (en) | Novel inhibitors | |
| EP2968358A4 (en) | NOVEL CHOLINKINASE INHIBITORS | |
| EP2986611A4 (en) | CERTAIN PROTEIN KINASE INHIBITORS | |
| GB201317609D0 (en) | Inhibitor compounds | |
| IL241325A0 (en) | Salt-induced macrocyclic kinase inhibitors | |
| IL241250A0 (en) | Macrocyclic inhibitors of rip2 kinase | |
| PT3030561T (pt) | N-cianometilamidas como inibidores de cinase janus | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| GB201304714D0 (en) | Macrocyclic RIP2 Kinase inhibitors | |
| GB201321328D0 (en) | Inhibitor compounds |